TScan Therapeutics, Inc.
TCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.09 | -0.02 | -0.02 |
| FCF Yield | -33.68% | -16.87% | -189.75% | -54.49% |
| EV / EBITDA | -2.16 | -4.26 | -0.05 | 1.05 |
| Quality | ||||
| ROIC | -39.16% | -37.55% | -35.01% | -28.60% |
| Gross Margin | 100.00% | -318.80% | 62.05% | 67.18% |
| Cash Conversion Ratio | 0.87 | 0.69 | 1.00 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | -40.75% | 27.56% | 131.92% | – |
| Free Cash Flow Growth | -77.74% | 8.80% | -20.66% | -707.30% |
| Safety | ||||
| Net Debt / EBITDA | 0.68 | 0.51 | 0.57 | 3.43 |
| Interest Coverage | -36.91 | -24.86 | -56.66 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -380.10 | -9.83 | -206.91 | -193.58 |